ArticleMolecular biology reports2026
Coordinated suppression of lectin complement pathway effectors and upregulation of SERPING1 defines a thrombo-inflammatory regulatory signature in Acute Coronary disease.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiovascular disease (CVD), the leading global cause of death, Acute coronary disease (ACS) is the highest mortality among CVD. Which is driven by thrombo-inflammatory processes involving oxidative stress, endothelial dysfunction, and innate immune dysregulation. The lectin complement pathway contributes to coagulation through thrombin-like activity and fibrin cross-linking, yet its transcriptional regulation under oxidative stress in human ACS remains unclear. We investigated whether acute coronary syndrome is associated with coordinated dysregulation of lectin pathway effector genes and the regulatory gene SERPING1.
methodsIn this cross-sectional study, 100 patients with clinically confirmed ACS and 50 healthy controls were enrolled. Systemic oxidative stress was assessed using serum superoxide dismutase (SOD), catalase (CAT), and malondialdehyde (MDA). The mRNA expression of MBL2, MASP1, MASP2, and SERPING1 was quantified in peripheral blood mononuclear cells (PBMCs) by RT-qPCR. ACS and control groups differed substantially in age, smoking, and alcohol use. The Mann-Whitney U test was used to compare continuous variables between the two independent groups, and multivariable linear regression was used to adjust for age, smoking, and alcohol use.
resultsACS patients showed significant oxidative imbalance, with reduced SOD (p < 0.0001), elevated MDA (p = 0.007), while CAT remained unchanged (p = 0.277) and significant downregulation of MBL2 (p = 0.017), MASP1 (p = 0.027), and MASP2 (p < 0.0001), alongside upregulation of SERPING1 (p = 0.001). After adjusting for age, smoking, and alcohol use, the association between ACS status and SERPING1 expression remained significant using both classical and heteroscedasticity-robust inference (adjusted p = 0.0007) and in an age-restricted sensitivity subsample (p = 0.003). The SOD reduction was attenuated to borderline significance after adjustment (robust p = 0.02), and the MBL2, MASP1, MASP2, and MDA associations did not reach significance after adjustment, indicating that these differences are substantially, though not necessarily entirely, explained by the between-group age and lifestyle imbalance.
conclusionsACS is associated with acute-phase systemic oxidative stress and altered lectin pathway gene expression, most notably a robust, adjustment-independent upregulation of SERPING1 that persists after accounting for age, smoking, and alcohol use. The downregulation of MBL2, MASP1, and MASP2 effector genes was attenuated after adjustment for these covariates and should be interpreted cautiously as a disease-associated signature until confirmed in age- and lifestyle-matched cohorts. These findings nonetheless identify SERPING1, and by extension the MASP-SERPING1 axis, as a candidate biomarker and therapeutic target meriting prospective, matched-cohort validation, with protein-level confirmation of the acute-phase transcriptional response captured here.
Indexed as
Identifiers
42606632What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.